NEW YORK--(BUSINESS WIRE)--The Rosen Law Firm, P.A. announces that it is investigating potential securities fraud claims against Northwest Biotherapeutics, Inc. (NASDAQ: NWBO) resulting from allegations that the Company may have made false and misleading disclosures concerning its experimental cancer vaccine, DCVax-Direct.
On June 19, 2014, TheStreet.com published a report stating that, "[t]he prestigious MD Anderson Cancer Center issued a stern rebuke to Northwest Biotherapeutics (NWBO) for making promotional, unjustified claims about results from an ongoing clinical trial of an experimental cancer vaccine known as DCVax-Direct." MD Anderson Cancer Center and two other hospitals are conducting the DCVAX-Direct study with funding from Northwest Biotherapeutics. In the article, Dr. Aman Buzdar, vice president of clinical research at MD Anderson, commented that “"I have read the information that the company has put in the public domain. It is extremely unusual and inappropriate."
On this news, shares of Northwest Biotherapeutics fell $1.44 per share to $7.53, or more than 16%, in intraday trading on June 19, 2014, damaging investors.
The Rosen Law Firm is preparing a class action lawsuit on behalf of Northwest Biotherapeutics investors. If you purchased NWBO securities prior to June 19, 2014, you may visit the website at http://rosenlegal.com to join the action. You may also contact Phillip Kim, Esq. or Kevin Chan, Esq. of The Rosen Law Firm toll free at 866-767-3653 or via e-mail at email@example.com or firstname.lastname@example.org.
The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
Attorney Advertising. Prior results do not guarantee a similar outcome.
Laurence Rosen, Esq.
Phillip Kim, Esq.
Kevin Chan, Esq.
The Rosen Law Firm P.A.
275 Madison Avenue, 34th Floor
New York, New York 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827